2-[[(2S,3R)-1-(dodecylamino)-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-6-hydroxynaphthalene-1-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-[[(2S,3R)-1-(dodecylamino)-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-6-hydroxynaphthalene-1-carboxylic acid
• 化学式: C₂₈H₄₀N₂O₆
• 分子量: 500.6
• InChiKey: BLOIICWDQUAJFA-CLOONOSVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  36
• 可旋转键数：
  16
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  136
• 氢给体数：
  5
• 氢受体数：
  6

文献信息

• SPHINGOLIPID METABOLITE MIMETICS
  申请人：Zhejiang University

  公开号：US20150031892A1

  公开（公告）日：2015-01-29

  Sphingolipid metabolite mimetics and methods of synthesizing them are provided. The sphingolipid metabolite mimetics are shown to be effective at inducing apoptosis in various types of tumor cells. Further, the sphingolipid metabolite mimetics are shown to be effective at sensitizing multiple types of tumor cells to TRAIL-induced apoptosis. Formulations containing one or more sphingolipid metabolite mimetics and, optionally, one or more cell death receptor agonists are provided. Methods of treating cancer in a subject in need thereof are provided using one or more sphingolipid metabolite mimetics.

  提供了类脂代谢物类似物及其合成方法。这些类脂代谢物类似物已被证明能够有效诱导各种类型的肿瘤细胞凋亡。此外，这些类脂代谢物类似物已被证明能够有效地使多种类型的肿瘤细胞对TRAIL诱导的凋亡产生敏感性。提供了包含一种或多种类脂代谢物类似物和可选地包含一种或多种细胞死亡受体激动剂的制剂。提供了使用一种或多种类脂代谢物类似物治疗需要的患有癌症的患者的方法。
• [EN] SPHINGOLIPID METABOLITE MIMETICS<br/>[FR] MIMÉTIQUES DE MÉTABOLITES SPHINGOLIPIDIQUES
  申请人：UNIV ZHEJIANG

  公开号：WO2014066613A2

  公开（公告）日：2014-05-01

  Sphingolipid metabolite mimetics and methods of synthesizing them are provided. The sphingolipid metabolite mimetics are shown to be effective at inducing apoptosis in various types of tumor cells. Further, the sphingolipid metabolite mimetics are shown to be effective at sensitizing multiple types of tumor cells to TRAIL-induced apoptosis. Formulations containing one or more sphingolipid metabolite mimetics and, optionally, one or more cell death receptor agonists are provided. Methods of treating cancer in a subject in need thereof are provided using one or more sphingolipid metabolite mimetics.